Logo
  • Portfolio
  • People
  • Investors
  • News
  • Contact Us
  • Portfolio
  • People
  • Investors
  • News
  • Contact Us

Year: 2024

News | 07/10/2024

CEO, Clive Dix joins In Vivo’s Ashley Yeo to discuss C4XD’s recent success with its PatientSeek platform, which has identified genetic signatures that predict patient response to vedolizumab in inflammatory bowel disease (IBD). 

Press Releases | 16/09/2024

PatientSeek identifies a genetic signature that separates a4b7 integrin therapy responder and non-responder populations in inflammatory bowel disease

Scientific Papers | 29/08/2024

Chemical modification of hyaluronan oligosaccharides differentially modulates hyaluronan-hyaladherin interactions

Press Releases | 22/07/2024

C4XD announces progress on immuno-inflammation programmes and appointment of new Board members

Scientific Papers | 04/07/2024

Unveiling new genetic insights in rheumatoid arthritis for drug discovery through Taxonomy3 analysis

Press Releases | 26/04/2024

Last day of dealings and update on Cancellation

Press Releases | 15/04/2024

Result of General Meeting

Press Releases | 08/04/2024

Vernalis announces a drug discovery collaboration with C4X Discovery in inflammatory disease

Press Releases | 27/03/2024

Proposed voluntary cancellation of admission of Ordinary Shares to trading on AIM

Press Releases |

Half-year results for the six months ended 31 January 2024

Posts navigation

Older posts

Categories

  • News
  • Press Releases
  • Scientific Papers

Archives

  • 2026
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020

Contact us

contact@c4xdiscovery.com

Copyright ©2026 C4XD Holdings Limited

privacy policy
  • Portfolio
  • People
  • Investors
  • News
  • Contact Us

C4X Discovery Holdings Ltd
1 Park Row
Leeds
LS1 5AB
United Kingdom

Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behaviour or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}